Luvox Effective For Treating Social Phobia
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Luvox Effective For Treating Social Phobia

SAN DIEGO, CA -- April 30, 1999 -- The drug Luvox (fluvoxamine) improves symptoms of social phobia and improves patients’ social, work and family life, according to researchers at University of California, San Diego School of Medicine.

The double-blind, placebo-controlled study was carried out at UCSD School of Medicine, Columbia University in New York, Duke University Medical Center in North Carolina, and Harvard Medical School in Boston. The results of the study are published in the May issue of the American Journal of Psychiatry.

This multi-center study demonstrates that a selective serotonin reuptake inhibitor (SSRI) is effective in treating social phobia, a serious and common psychiatric disorder in which sufferers have an extreme fear of being scrutinized or behaving in an embarrassing or humiliating way in front of others.

"In this study we found that fluvoxamine is effective, has few side effects and carries no risk for abuse or dependency," said lead author Murray Stein, M.D., professor of psychiatry at the UCSD School of Medicine. "This is an important new option for patients." Stein is also director of the Anxiety and Traumatic Stress Disorders Clinic at the Veterans Affairs Medical Center in La Jolla.

They treated 90 patients for 12 weeks with either fluvoxamine or a placebo. Significantly more patients in the fluvoxamine group than in the placebo group responded to treatment (43 percent vs. 23 percent). The drug was also more effective than placebo in improving disruption in work, social life and family life.

Social phobia, or social anxiety disorder, is the third most common psychiatric disorder in the United States, affecting more than 5 million Americans each year. People with the condition try at all costs to avoid situations where scrutiny may occur, such as meeting new people, using the telephone, and eating or speaking in public. When forced to confront these situations, people with social phobia suffer intense apprehension and fear that may be accompanied by symptoms such as sweating, stomach cramps, trembling or headaches.

This disorder often co-exists with other mental illnesses, including obsessive compulsive disorder, panic disorder, depression, eating disorders, alcoholism or drug abuse. In fact, two out of three social phobia sufferers will develop another psychiatric disorder at some time during their lives. One in 10 social phobia sufferers will attempt suicide at some time during their illness.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities